Brainsway Ltd (IL:BWAY)
TASE:BWAY
Want to see IL:BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
3718.00
0.01(0.06%)
At close: 4:00 PM EST
3718.00
0.01(0.06%)
Day’s Range― - ―
52-Week Range1,930.00 - 5,123.00
Previous CloseN/A
Volume32.24K
Average Volume (3M)85.46K
Market Cap
₪1.69B
Enterprise Value524.11M
Total Cash (Recent Filing)₪59.77M
Total Debt (Recent Filing)₪6.71M
Price to Earnings (P/E)62.0
Beta0.29
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding40,123,720
10 Day Avg. Volume88,081
30 Day Avg. Volume85,462
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.11
Price to Sales (P/S)6.62
P/FCF Ratio23.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Profitability & Margin StrengthBrainsWay has converted to consistent profitability with very high gross margins (~75%) and recurring adjusted EBITDA growth. Durable margins and repeated profitable quarters support reinvestment in sales, R&D and clinical validation, improving long‑term scalability and ability to fund growth internally.
Conservative Balance Sheet & Cash BufferA strong cash position and minimal leverage (low debt-to-equity) provide financial flexibility to fund commercial expansion, clinic investments and strategic R&D without near-term refinancing risk. This balance-sheet conservatism materially reduces solvency risk over the next several quarters.
Installed Base Growth & Revenue VisibilityRapid unit placements and a growing installed base create a durable recurring revenue stream from consumables, service and treatment utilization. Larger installed base plus rising RPO ($75M reported) improve multi-year revenue visibility and support predictable aftermarket growth.
Bears Say
Cash-Flow Conversion WeaknessDespite profitability, operating cash flow lagging net income and a material FCF decline indicate working-capital or timing challenges. Persistent conversion shortfalls can constrain organic investment, make guidance harder to achieve, and elevate sensitivity to quarter‑to‑quarter execution.
Dependence On Payer Adoption For GrowthLong-term uptake of Deep TMS and new protocols like SWIFT depends on durable payer coverage and policy changes. Delays or limited reimbursement adoption would materially slow clinic adoption, utilization and recurring revenue, making top-line growth contingent on external policy timelines.
Early-stage Neurolief Exposure & Execution RiskSignificant upside from ProlivRx rests on a partner (Neurolief) executing VA/IDN rollouts and meeting milestones; BrainsWay's exposure is creditor-like and contingent. If milestones or adoption falter, expected strategic benefits and returns on investment may not materialize, risking capital and opportunity cost.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was 1930.00 and its highest was 5123.00 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is ₪1.69B.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Aug 12, 2026 which is in 53 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on May 13, 2026. The company reported 17.8 earnings per share for the quarter, beating the consensus estimate of N/A by 17.8.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,123,720 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of 17.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.277%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in IL:BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainsway Ltd
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatric practitioners, hospitals, and medical centers across the United States, Europe, Israel, and other international markets.
BWAY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational quarter with broad revenue and profitability gains, meaningful clinical and payer progress (notably SWIFT), a growing installed base and a solid cash position. Strategic investments (minority clinic stakes and Neurolief funding) and international momentum support long-term growth, but the company is making tradeoffs by increasing operating investments and remains partially dependent on payer coverage and milestone-driven commercialization paths. Overall, positives—robust top-line growth, margin expansion, RPO improvement and clinical validation—materially outweigh the risks, though execution and reimbursement timing will be critical to sustain momentum.View all IL:BWAY earnings summaries